Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Choosing between equal and cap weight depends on goals and risk tolerance. This quick guide compares the two for retirement suitability.
24,468 articlesLilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
One year after the pledge, the Strategic Petroleum Reserve remains short of full capacity while crude prices push pas...
Wegovy continues to lead the U.S. GLP-1 market despite Eli Lilly's Foundayo launch. Investors are weighing uptake, pa...
When a CEO disposes of stock, investors want context. This deep dive explains what fastly's sold company shares could...
Eli Lilly stock is surging on fresh obesity-drug data, fueling bets that the name could push toward a record high wit...
A bestselling author behind Rich Dad Poor Dad signals a looming market bust and presents a crisis-era bitcoin price p...
A wave of data center spending powered by AI is reshaping the investment landscape. This article explains which stock...
When a billionaire makes a bold AI stock bet, everyday investors seek a clear path forward. This guide breaks down th...
An upbeat quarterly report sent accelerant holdings stock skyrocketed higher by double digits. This piece breaks down...
When a notable hedge fund exits a sizable stake, it prompts questions about the underlying thesis. This article digs ...
A decade-long income lure from QYLD masks a sizable NAV erosion. The ETF's NAV has declined about 35% since its 2013 ...
A quiet pivot is reshaping a once purely crypto-focused business. This former bitcoin miner is transitioning into AI-...